Midazolam Placebo Solution + Esketamine for major depressive disorder

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Jun 2017: Trial registered, NCT03185819
  2. 5 Oct 2017: Trial started, NCT03185819

The trials

NCT03185819: Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

State
Completed
Phase
Phase 2
People
147 taking part
Started
5 Oct 2017
Primary completion
31 Mar 2023
Arms
Oral Placebo + Esketamine 84 mg, Oral Placebo + Esketamine 56 mg, Oral Placebo + Esketamine 28 mg
Results
Posted on the registry
  1. 14 Jun 2017: Trial registered
  2. 5 Oct 2017: Trial started
  3. 31 Mar 2023: Trial completed
  4. 17 Apr 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.